⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCNX News
Scienture Holdings, Inc. Common Stock
Form 8-K
sec.gov
SCNX
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
globenewswire.com
SCNX
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
globenewswire.com
SCNX
Form 8-K
sec.gov
NXNT
SCNX
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
globenewswire.com
SCNX
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
globenewswire.com
SCNX
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
globenewswire.com
SCNX
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
globenewswire.com
SCNX
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
globenewswire.com
SCNX
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
accessnewswire.com
DGXX
DYAI
STRT
GAME
ACNT
RNXT
DCGO
BOSC
SCNX
ELWT
MOB
VELO
FLUX